Clinical trial · Observational
HRD and Resistance to PAPPi in EOC Patients
Correlation Between Homologous Recombination Deficiency Status and Resistance to PARP Inhibitors in Chinese Epithelial Ovarian Cancer Patients
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The association between homologous recombination (HR) gene mutations and homologous recombination deficiency (HRD) status in Chinese epithelial ovarian cancer (EOC) patients has been investigated in previous studies (NCT04190667 and NCT04651920). This study is to investigate the correlation between HRD and the resistance to poly(ADP-ribose) polymerase inhibitors (PARPi) in a Chinese cohort confirmed of epithelial ovarian cancer. The mutated genes, HRD score model and their relationship with the prognosis is the primary endpoint in this study. All enrolled patients will accept PARPi as maintenance therapy after the complete or partial remission of targeted lesions. A multiple panel testing of germline and somatic genes, including BRCA1/2, and HRD score are provided for all participants.
Conditions
Conditions (7)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Drug Resistance | — | UNRESOLVED | — |
| Epithelial Ovarian Cancer | Ovarian Carcinoma | ALIAS | 0.90 |
| Homologous Recombination Deficiency | — | UNRESOLVED | — |
| Homologous Recombination Repair Gene Mutation | — | UNRESOLVED | — |
| Overall Survival | — | UNRESOLVED | — |
| Poly(ADP-ribose) Polymerase Inhibitor | — | UNRESOLVED | — |
| Progression-free Survival | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Testing of homologous recombination deficiency | Genetic | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Progression-free survival
- timeFrame
- One year
- description
- Progression-free survival after the start of PARPi
Secondary outcomes (2)
- measure
- Overall survival
- timeFrame
- One year
- description
- Overall survival after the start of PARPi
- measure
- Severe adverse events
- timeFrame
- One year
- description
- Severe adverse events after the start of PARPi
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Aged 18 years or older * Pathological confirmation of epithelial ovarian cancer * With available tumor tissues * Given consents to participate the study * With detailed follow-up outcomes Exclusion Criteria: * Not meeting all of the inclusion criteria * Declining to accept PARPi as maintenance therapy after the major treatment for cancer
References
Publications (0)
Data not yet available